These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26735017)

  • 1. Cancer: Bet on drug resistance.
    Settleman J
    Nature; 2016 Jan; 529(7586):289-90. PubMed ID: 26735017
    [No Abstract]   [Full Text] [Related]  

  • 2. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
    Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
    Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?
    Yao D; Liu J; Ouyang L
    Future Med Chem; 2017 Jun; 9(9):839-842. PubMed ID: 28635318
    [No Abstract]   [Full Text] [Related]  

  • 5. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure: BRD4 inhibition slows HF progression.
    Ummarino D
    Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569271
    [No Abstract]   [Full Text] [Related]  

  • 7. BRD4: a BET(ter) target for the treatment of AML?
    Valent P; Zuber J
    Cell Cycle; 2014; 13(5):689-90. PubMed ID: 24526121
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
    Shu S; Wu HJ; Ge JY; Zeid R; Harris IS; Jovanović B; Murphy K; Wang B; Qiu X; Endress JE; Reyes J; Lim K; Font-Tello A; Syamala S; Xiao T; Reddy Chilamakuri CS; Papachristou EK; D'Santos C; Anand J; Hinohara K; Li W; McDonald TO; Luoma A; Modiste RJ; Nguyen QD; Michel B; Cejas P; Kadoch C; Jaffe JD; Wucherpfennig KW; Qi J; Liu XS; Long H; Brown M; Carroll JS; Brugge JS; Bradner J; Michor F; Polyak K
    Mol Cell; 2020 Jun; 78(6):1096-1113.e8. PubMed ID: 32416067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
    Devaraj SG; Fiskus W; Shah B; Qi J; Sun B; Iyer SP; Sharma S; Bradner JE; Bhalla KN
    Leukemia; 2016 Feb; 30(2):504-8. PubMed ID: 26148704
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting the BET family for the treatment of leukemia.
    Lucas X; Günther S
    Epigenomics; 2014 Apr; 6(2):153-5. PubMed ID: 24811781
    [No Abstract]   [Full Text] [Related]  

  • 12. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer research: Open ambition.
    Maxmen A
    Nature; 2012 Aug; 488(7410):148-50. PubMed ID: 22874946
    [No Abstract]   [Full Text] [Related]  

  • 14. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
    Qi J
    Cold Spring Harb Perspect Biol; 2014 Dec; 6(12):a018663. PubMed ID: 25452384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BETs abet Tam-R in ER-positive breast cancer.
    Alluri PG; Asangani IA; Chinnaiyan AM
    Cell Res; 2014 Aug; 24(8):899-900. PubMed ID: 25001387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phthalimide-Conjugated Ligands Promote Selective Protein Destabilization.
    Cancer Discov; 2015 Jul; 5(7):691. PubMed ID: 26045013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First drugs found to inhibit elusive cancer target.
    Moyer MW
    Nat Med; 2011 Nov; 17(11):1325. PubMed ID: 22064391
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.